Description
Multiple myeloma (MM) is marked by multiple subclones exhibiting high mutational burden and chromosomal abnormalities. It arises from expanding pre-existing clonal populations such as monoclonal gammopathy of uncertain significance (MGUS) or smoldering multiple myeloma (SMM). Despite lacking symptoms, these precursor conditions are linked to early genetic events involving driver mutations and clonal changes. As myeloma cells expand, clonal genetic differences also contribute to relapse with acquired resistance in almost all patients, suggesting that initial therapy is inadequate to eradicate the disease. Thus, a more comprehensive identification of subclones driving disease progression or drug resistance is imperative to curb active MM development and optimize precision therapy application.
In this webinar, Adam Sciambi, PhD, CTO at Mission Bio, will provide a sneak peek preview of an upcoming single-cell mutli-omics assay that uncovers complex clonal heterogeneity underlying myeloma evolution and biology, and share novel data identifying the clonal populations that progress to active MM or resistant disease.
